Drug intelligence / Profile preview

DYRECT

Development stage: Unknown
Lead developer: Ozone Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**DYRECT** is an oral fixed-dose pain-management product marketed by Ozone Pharmaceuticals. Each enteric-coated tablet contains diclofenac potassium 50 mg and serratiopeptidase 10 mg. Diclofenac is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes and reduces prostaglandin-mediated pain and inflammation; serratiopeptidase is a proteolytic enzyme used for its anti-inflammatory and anti-edema activity. The product is marketed for pain and inflammatory conditions.

Brand names: DYRECT

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on DYRECT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DYRECT.

Explore the full profile